Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma

被引:22
作者
Chang, James M. [1 ]
McCullough, Ann E. [2 ]
Dueck, Amylou C. [3 ]
Kosiorek, Heidi E. [3 ]
Ocal, Idris T. [2 ]
Lidner, Thomas K. [2 ]
Gray, Richard J. [1 ]
Wasif, Nabil [1 ]
Northfelt, Donald W. [4 ]
Anderson, Karen S. [4 ,5 ]
Pockaj, Barbara A. [1 ]
机构
[1] Mayo Clin, Dept Surg, Phoenix, AZ 85054 USA
[2] Mayo Clin, Dept Pathol, Phoenix, AZ USA
[3] Mayo Clin, Biostat Sect, Phoenix, AZ USA
[4] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[5] Arizona State Univ, Biodesign Inst, Tempe, AZ USA
关键词
DX RECURRENCE SCORE; PATHOLOGICAL PROGNOSTIC FACTORS; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; PATIENTS YOUNGER; ACTIVITY INDEX; FOLLOW-UP; PROLIFERATION; REPRODUCIBILITY;
D O I
10.1245/s10434-015-4616-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Newer multigene molecular profiling assays for breast carcinoma rely heavily on the quantification of genes of proliferation, whereas traditional histological grading reports the mitotic count. The mitotic activity of invasive breast carcinomas may be undervalued; therefore, an evaluation of the prognostic significance of mitotic score in predicting prognosis was performed. Methods. Retrospective analysis of a single institutional cohort of newly diagnosed estrogen receptor positive (ER+), HER2 negative (HER2-) unilateral invasive breast carcinomas was performed. Mitotic scores from the 3-part Nottingham combined histological grade were compared with clinical parameters. Mitoses were counted on Olympus BX50 microscopes and assigned scores of 1-3 based on observed mitoses. Results. A total of 1292 ER+, HER2- invasive breast carcinoma patients were identified, with a median followup time of 2.6 years (range 0-14 years). Higher mitotic score was significantly associated with younger age, larger tumor size, angiolymphatic invasion, node-positive disease, higher stage, and the use of hormonal and cytotoxic chemotherapy. Mitotic score was significant in modeling time to local/regional recurrence (p = 0.02), recurrencefree survival/RFS (p < 0.001), and overall survival/OS (p = 0.01) with higher mitotic scores associated with worse outcomes. Higher mitotic score correlated significantly with intermediate/high risk Oncotype Dx recurrence scores (p = 0.009). Conclusions. First-generation molecular profiling assays for estrogen receptor positive invasive breast carcinomas derive much of their predictive power from quantifying genes of proliferation into a single score. Sometimes overlooked in the profusion of molecular data, the time-tested, mitotic count in the Nottingham combined histological grade is a good single-parameter predictor of survival.
引用
收藏
页码:S509 / S515
页数:7
相关论文
共 37 条
  • [11] A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
    Habel, Laurel A.
    Shak, Steven
    Jacobs, Marlena K.
    Capra, Angela
    Alexander, Claire
    Pho, Mylan
    Baker, Joffre
    Walker, Michael
    Watson, Drew
    Hackett, James
    T Blick, Noelle
    Greenberg, Deborah
    Fehrenbacher, Louis
    Langholz, Bryan
    Quesenberry, Charles P.
    [J]. BREAST CANCER RESEARCH, 2006, 8 (03)
  • [12] HENSON DE, 1991, CANCER-AM CANCER SOC, V68, P2142, DOI 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO
  • [13] 2-D
  • [14] Jasani B., 2005, Pathology reporting of breast disease
  • [15] Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
    Klein, Molly E.
    Dabbs, David J.
    Shuai, Yongli
    Brufsky, Adam M.
    Jankowitz, Rachel
    Puhalla, Shannon L.
    Bhargava, Rohit
    [J]. MODERN PATHOLOGY, 2013, 26 (05) : 658 - 664
  • [16] Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
    Lakhani, SR
    Jacquemier, J
    Sloane, JP
    Gusterson, BA
    Anderson, TJ
    van de Vijver, MJ
    Farid, LM
    Venter, D
    Antoniou, A
    Storfer-Isser, A
    Smyth, E
    Steel, CM
    Haites, N
    Scott, RJ
    Goldgar, D
    Neuhausen, S
    Daly, PA
    Ormiston, W
    McManus, R
    Scherneck, S
    Ponder, BAJ
    Ford, D
    Peto, J
    Stoppa-Lyonnet, D
    Bignon, YJ
    Struewing, JP
    Spurr, NK
    Bishop, DT
    Klijn, JGM
    Devilee, P
    Cornelisse, CJ
    Lasset, C
    Lenoir, G
    Barkardottir, RB
    Egilsson, V
    Hamann, U
    Chang-Claude, J
    Sobol, H
    Weber, B
    Stratton, MR
    Easton, DF
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (15): : 1138 - 1145
  • [17] In Patients Younger Than Age 55 Years With Lymph Node-Negative Breast Cancer, Proliferation by Mitotic Activity Index Is Prognostically Superior to Adjuvant!
    Lende, Tone Hoel
    Janssen, Emiel A. M.
    Gudlaugsson, Einar
    Voorhorst, Feja
    Smaaland, Rune
    van Diest, Paul
    Soiland, Havard
    Baak, Jan P. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 852 - 858
  • [18] Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer:: Results from a nationwide study
    Lundin, J
    Lundin, M
    Holli, K
    Kataja, V
    Elomaa, L
    Pylkkänen, L
    Turpeenniemi-Hujanen, T
    Joensuu, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 28 - 36
  • [19] Mitotic counts provide additional prognostic information in grade II mammary carcinoma
    Lynch, J
    Pattekar, R
    Barnes, DM
    Hanby, AM
    Camplejohn, RS
    Ryder, K
    Gillett, CE
    [J]. JOURNAL OF PATHOLOGY, 2002, 196 (03) : 275 - 279
  • [20] Mandard AM, 2000, CANCER, V89, P1748, DOI 10.1002/1097-0142(20001015)89:8<1748::AID-CNCR15>3.0.CO